Risk Factors Update Summary

• Recorded net losses increased from $46.8 million in 2021 to $61.7 million in 2022.
• Addition of Symatese as a supplier may impact regulatory compliance and product development.
• Net losses further increased to $74.4 million for the year ended December 31, 2023.
• Federal NOLs decreased from $318.8 million to $317.7 million as of December 31, 2023.
• Increase in common stock shares from 57,820,621 to 57,820,621 may affect ownership dynamics.
• Accumulated deficit rose from $497 million as of December 31, 2022, to $559 million in 2023.
• State NOLs increased from $214.3 million to $227.3 million as of December 31, 2023.
• Reduction in ownership percentages by Medytox from 13% to 5% and Daewoong from 5.6% to 4%.
• Number of employees increased from 215 to 273 as of December 31, 2023.
• Stock price fluctuations from a low of $5.15 to a high of $13.11 may impact investor sentiment.
• Change in the composition of the Board of Directors could lead to operational disruptions.
• Potential sale of a substantial number of shares by major stockholders may affect stock price.
• Inclusion of geopolitical conflicts beyond the Russian-Ukrainian conflict as a risk factor.